BRAF and cancer: In addition, histone deacetylase inhibition is reported to deplete quiescent stem-like cells in multiple cancer types 219, 220, and a strategy to combine drug holidays with vorinostat, a histone deacetylase inhibitor, has shown better effects than the combination of BRAF-MEK inhibitors in a melanoma model 221.